GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, Germany/BOSTON, USA – September 12, 2024 – CureVac N.V ...
After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...
Germany has begun new controls at all of its land borders as part of a crackdown on migration, placing restrictions on a wide area of free movement known as the Schengen Zone and stirring anger ...
GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...
GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...
TÜBINGEN, GERMANY and BOSTON, MA - GlaxoSmithKline (NYSE:GSK) has reported encouraging Phase 2 results for its mRNA-based seasonal influenza vaccine, which utilizes technology from ...
GSK’s depemokimab, a new ultra-long-acting biologic, showed a 54% reduction in severe asthma exacerbations in the SWIFT-1 and ...
A ranking of the top songs based on streaming and sales activity from within the country- as tracked by Luminate. The ranking is based on a weighted formula incorporating official-only streams ...
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback